(MedPage Today) — HOUSTON — Already indicated for relapsed/refractory follicular lymphoma, the bispecific antibody mosunetuzumab (Lunsumio) showed early promise for improving outcomes in two key lymphoma subtypes, according to studies reported…
Source link : https://www.medpagetoday.com/meetingcoverage/soho/117371
Author :
Publish date : 2025-09-09 14:53:00
Copyright for syndicated content belongs to the linked Source.
